The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer by Matos, Bárbara et al.
1 
 
The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer 
Bárbara Matos1, John Howl2, Carmen Jerónimo3,4, Margarida Fardilha1 
 
1 Laboratory of Signal Transduction, Department of Medical Sciences, Institute of Biomedicine 
– iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal 
2 Molecular Pharmacology Group, Research Institute in Healthcare Science, University of 
Wolverhampton, Wolverhampton WV1 1LY, UK 
3 Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese 
Institute of Oncology of Porto (IPO Porto), Research Center-LAB 3, F Bdg., 1st floor, Rua Dr. 
António Bernardino de Almeida, 4200-072 Porto, Portugal 
4 Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel 











Margarida Fardilha, PhD 
Department of Medical Sciences, Institute of Biomedicine – iBiMED, University of Aveiro, 









Prostate cancer (PCa) is one of the most common male-specific cancers worldwide, with high 
morbidity and mortality rates associated with advanced disease stages. The current 
treatment options of PCa are prostatectomy, hormonal therapy, chemotherapy or 
radiotherapy, the selection of which is usually dependent upon the stage of the disease. The 
development of PCa to a castration-resistant phenotype (CRPC) is associated with a more 
severe prognosis requiring the development of a new and effective therapy. Protein-protein 
interactions (PPIs) have been recognised as an emerging drug modality and targeting PPIs is 
a promising therapeutic approach for several diseases, including cancer. The efficacy of 
several compounds in which target PPIs and consequently impair disease progression were 
validated in phase I/II clinical trials for different types of cancer. In PCa, various small 
molecules and peptides proved successful in inhibiting important PPIs, mainly associated with 
the androgen receptor (AR), Bcl-2 family proteins, and kinases/phosphatases, thus impairing 
the growth of PCa cells in vitro. Moreover, a majority of these compounds require further 
validation in vivo and, preferably, in clinical trials. In addition, several other PPIs associated 
with PCa progression have been identified and now require experimental validation as 
potential therapeutic loci.  
In conclusion, we consider the disruption of PPIs to be a promising though challenging 
therapeutic strategy for PCa. Agents which modulate PPIs might be employed as a 
monotherapy or as an adjunct to classical chemotherapeutics to overcome drug resistance 
and improve efficacy. The discovery of new PPIs with important roles in disease progression, 
and of novel optimized strategies to target them, are major challenges for the scientific and 
pharmacological communities. 
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Prostate cancer (PCa) is the second most common type of cancer and the fifth leading cause 
of cancer-associated mortality among men worldwide[1]. The PCa treatment is critically 
dependent upon the stage of the disease. Frequently, in early-stage and localized disease, the 
radical prostatectomy or local radiotherapy are the preferred treatment options for PCa. 
When the tumor has spread outside of the prostate, or if first-line treatments fail, hormone 
therapy is then employed. Hormone therapy is applied since PCa cells growth are highly 
dependent on androgens. This type of treatment consists on deplete, often through 
castration, or block the action of androgens. Overall, these treatment options are associated 
with a good survival rate[2,3]. Nevertheless, in a non-negligible number of cases, PCa adapts 
to survive and grow under castration levels of androgens, becoming castration-resistant 
(CRPC). The molecular mechanisms through which CRPC develops are not fully clarified; 
however the amplification of androgen receptor (AR), the expression of AR splice variants, an 
increased interaction of AR with its coactivators and secondary androgen production by PCa 
cells are likely contributing factors[4,5]. Indeed, the AR is considered a vital driver of CRPC 
progression and most of the first-line current treatments for CRPC are based on targeting the 
AR signaling pathway. Besides AR signaling, other pathways seem to be dysregulated in CRPC 
and have emerged as CRPC drug targets. These alternative targets include PI3K/Akt/mTOR, 
Wnt/ β-catenin and Hippo signaling pathways[6–8]. The therapeutic manipulation of heat 
shock proteins (HSPs) and AR co-activators has also been proposed for CRPC treatment. 
Unfortunately, and despite these many potential therapeutic advancements, the prognosis 
for CRPC patients remains unsatisfactory and the development of  an effective treatment for 
CRPC remains  a major challenge [5,9]. 
Protein-protein interactions (PPIs) and micro-RNA-target interactions were considered 
important in deciphering the mechanisms of tumorigenesis and were proposed as potential 
therapeutic biomarkers[10–12]. Targeting PPIs has emerged as a promising therapeutic 
approach for several types of cancer. In the last decades, large scale efforts have surveyed 
and catalogued PPIs which, collectively, constitute the human interactome[13,14]. These 
studies have identified a large number of PPIs with critical influences upon major signalling 
pathways. Indeed, though many PPIs lack detailed characterization, their involvement in 
critical cellular functions, including cell growth and differentiation, DNA replication, 
4 
 
transcriptional activation, translation and transmembrane signal transduction is 
evident[15,16]. Deregulation of these protein interactions is often associated with pathologic 
conditions. In fact, more than 650, 000 disease-relevant PPIs have been reported, however 
about 98% of these interactions remain underexplored[17]. 
Predominantly because of their highly complex and dynamic nature, PPIs have traditionally 
been considered “undruggable”. Nevertheless, in response to advancements in technological 
expertise, coupled with increased scientific knowledge, PPIs have emerged as a promising 
drug targets [14].  Consequently, recent years have witnessed an exponential increase in 
reports detailing the successful disruption of PPIs, with an emphasis upon diseases of the 
brain and cardiovascular system [15.16]. 
In this context, we have rigorously reviewed the potential of PPI disruption as a therapeutic 
strategy for PCa. Herein, we summarize a range of contemporary approaches and their 
outcomes.  We also describe potential PPIs that, whilst their disruption has not yet been 
tested, are associated with disease progression. Finally, we highlight the most significant 
conclusions to be drawn from such studies and elaborate upon future research opportunities 
in the field. 
2. Targeting PPIs in cancer 
The knowledge of cancer genomics is essential to the molecular characterization of human 
cancers since it allows the definition of cancer-associated genes and their respective proteins. 
Recently, attention is turning towards the  understanding of how these proteins interact and 
form PPIs that contribute to dysregulated oncogenic pathways[18]. Despite most of the 
current PPIs databases do not contain cancer-specific analysis, several attempts have been 
made to identify cancer-associated PPIs. In addition, dysregulation of various PPIs was 
associated with cancer initiation and/or progression. First, based upon lung cancer-associated 
genes libraries, Li et al (2017)[19] identified 260 cancer-associated PPIs. Thereafter, Ivanov et 
al (2018)[20] integrated all the available information about PPIs with roles in lung cancer to 
create an integrative resource named OncoPPI Portal. This platform comprises more than 
2500 cancer-associated PPIs. Curiously, about 85% of cancer-associated PPIs are novel, when 
compared with those described in public databases, indicating that most of them are 
exclusive to cancer tissues. More recently, a pan-cancer mapping of differential PPIs was 
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performed by Gulfidan et al (2020)[21]. A total of 2039 cancer-associated PPIs were common 
to eleven of all types of cancer investigated[21]. Nevertheless, the currently available tools 
for exploring oncogenic PPIs networks are limited and the identification of cancer-related PPIs 
remains challenging[20].  
The important role of PPIs in forming signaling networks that transmit pathophysiological 
signals to achieve an integrated biological output, allowing the acquisition of hallmark 
features of cancer, is well established. Indeed, the involvement of PPIs in tumorigenesis, 
tumor progression, invasion and metastasis have been reported[21,22]. Individually and 
collectively, these findings suggest that the disruption of PPIs critical for cancer progression 
could offer a novel and effective therapeutic strategy[12].  
Thus, in recent years, PPIs, that have long been considered “undruggable” have developed 
into attractive molecular targets for novel anticancer therapies. Nevertheless, it has been 
shown that only about 32% of cancer-associated PPIs are druggable[21]. The development of 
PPI inhibitors remains a time-consuming, expensive, and difficult process, which should only 
be initiated for the best validated targets. Indeed, it is estimated that only a small proportion 
of the proposed compounds is successfully tested in clinical trials[23]. The significant 
challenges associated with the targeting of  PPIs are a consequence of their large interface 
areas, lack of deep pockets, presence of non-contiguous binding sites, general lack of natural 
ligands, and the intracellular location of most of them[12]. In general, PPI inhibitors should be 
able to enter into the cell and mimic the binding hotspots which support discrete protein 
interactions to ensure high affinity binding; retain some proprieties of the same target to 
overcome drug resistance; and be active not only to the proposed PPIs, but also their 
paralogs[24]. These challenges can, however, be overcome so today there are multiple 
examples of PPI inhibitors with beneficial results for different types of cancer[25–27], 
including PCa. Most of them have been exclusively analysed in vitro, and pre-clinical and 
clinical validations are still required to confirm their therapeutic effects.  
To the best of our knowledge, to date, 14 small molecule PPI inhibitors have been subjected 
to clinical trials as possible anticancer therapies. These compounds inhibit PPIs belonging to 
three main pathways: Bcl family inhibitors[28–34], MDM2-p53 inhibitors[35–40] and SMAC-
XIAP inhibitors[41–45]. In Phase I/II clinical trials of gossypol and its R enantiomer, a limited 
efficacy was demonstrated in breast and prostate cancers[28,29]. Other Bcl2 inhibitors 
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(Obatoclax, Navitoclax and Venetoclax) were tested in a phase I study and despite some side 
effects, they were well tolerated and safe. These compounds exhibited considerable clinical 
activities for lung cancer, lymphoma and acute myelogenous leukemia[30–32,34]. Navitoclax 
was associated with limited single-agent activity and combination with other drugs was 
suggested, while Venetoclax had significant antitumor activity as a single-agent, in Phase II 
clinical trials[33,34]. Several MDM2-p53 inhibitors were also evaluated in Phase I clinical 
trials. In particular, RG7112, RG7388, DS-3032b, HK-8242 and JNJ-26854165 demonstrated 
acceptable safety and tolerability, and evidence of clinical activity against solid tumors and 
lymphoma. Most of them also restored the p53 tumor suppressor activity[35–40]. The SMAC-
XIAP inhibitors AT-406, GDC-01542, GDC-0917 and HGS1029 were safe and tolerable for most 
solid tumors and lymphoma[41–44]. The oral administration of AT-406 was tested in a Phase 
II clinical trial and limited antitumor activity was observed. This compound was suggested as 
an adjuvant of classic anticancer therapy[41]. Thus, many PPIs inhibitors tested in clinical trials 
proved successful either as monotherapy or in combination with classic chemotherapeutic 
agents, for several types of cancer. 
3. Evidence acquisition 
A relevant bibliography was selected after an extensive Web of Science search up to April 15th 
2020, using the keywords: ”protein protein interaction”, “disruption” and “prostate cancer”. 
Reference lists from the articles were also examined for potentially useful studies. 
Furthermore, enrolled articles were selected if following the next criteria: written in English, 
central theme based on disruption of PPIs in PCa, and clinical relevance for PCa treatment. 
4. Targeting PPIs in PCa: what has been done? 
4.1. PPIs targeted by small molecules 
In recent years, one of the major goals of drug discovery has been the development of small 
molecules with the ability to target specific PPIs[46]. Despite the challenges associated with 
this strategy, particularly the extended surface areas of PPI interfaces, several small organic 
molecules proved successful in blocking PPIs with important roles in disease progression, both 
in vitro and in vivo[47]. The main studies in this topic are summarized in the following sections 
(Table 1). 
4.1.1. Androgen receptor (AR)-related PPIs 
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Androgens, acting through the AR, are essential for prostate development and homeostasis. 
AR signaling has been associated with tumor growth, anti-apoptotic ability and dysregulated 
lipid pathway in PCa[48,49]. Indeed, AR, as a nuclear receptor, facilitates ligand-dependent 
transcriptional activation and interacts with several tissue-specific transcriptional factors, 
inducing the proliferation of prostate epithelial cells and PCa tumor growth[50]. Thus, 
targeting androgens and AR signaling are considered therapeutic strategies for the majority 
of prostate tumors[51]. Androgen deprivation therapy is one of the mainstays of PCa 
treatment, as it can suppress the disease progression. Moreover, targeting the AR axis has 
also been considered the first-line approach in the treatment of PCa, when it evolves to CRPC, 
since AR alterations are the main features of this condition. More recently, the disruption of 
PPIs involving AR with small molecules emerged as a strategy to affect the dysregulated 
signaling pathways, resulting in a better outcome for PCa patients. This approach has led to 
some promising results (Table 1). 
Since AR transcriptional activity is modulated by coregulatory proteins, it is logical to consider 
these PPIs as targets for agents designed to decrease AR transactivation[52]. Hence, two small 
molecule compounds were developed to disrupt interactions of AR with its coactivators. The 
pterostilbene (PTER)-isothiocyanate (ITC) conjugate was associated with anti-androgenic 
proprieties, by disrupting AR interaction with its coactivators SRC-1 and GRIP-1, 
downregulating AR activity (Figure 1A). Thus, PTER-ITC caused accumulation of PCa cells in 
the G2/M phase and  induced apoptosis[53]. The disruption of AR interaction with its 
coactivator β-catenin was also achieved using a small inhibitor of nuclear β-catenin activity, 
named iCRT3. The disruption of this interaction resulted in inhibition of PCa cell proliferation 
(Figure 1A)[54] and  repression of tumor growth in mice xenografts[54]. Moreover, an 
aberrant activation of AR through Wnt/β-catenin signaling was associated with the 
progression of PCa to CRPC[5], suggesting that iCRT3 may have also a beneficial effect in CRPC 
treatment. Nevertheless, this compound was also described as an inhibitor of TCF/β-catenin 
and thus affects the Wnt pathway. Targeting this signaling pathway has been associated with 
several limitations. The important role of this signaling pathway in the developmental process 
and in tissue homeostasis by regulating a wide range of cellular processes, makes it difficult 
to discretely modulate this pathway without significant side effects. Indeed, and despite 
substantial efforts from the scientific and pharmacological communities to circumvent these 
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limitations, no therapeutic agent targeting the Wnt pathway is currently approved for cancer 
therapy[55]. 
The AR interacts with several HSPs, contributing to PCa cell survival and proliferation[56]. The 
beneficial effect of ailanthone in inhibiting tumor growth was demonstrated both in vitro and 
in vivo and was associated with the disruption of AR/HSP90 interaction. Indeed, ailanthone, a 
natural compound recognized as a potent inhibitor of AR, could reduce AR nuclear 
translocation by targeting the co-chaperone protein p23, and thus preventing the interaction 
of AR with HSP90 (Figure 1B). This small molecule was also associated with decreased CRPC 
cells proliferation and metastasis[57]. Enzalutamide is an antagonist of AR and is the first 
therapeutic approach for CRPC. However, a significant percentage of CRPC tumors develop 
resistance to this drug. Ailanthone also offers advantages in overcoming this drug-resistance 
associated with many CRPC[57]. The administration of this small molecule in mice xenografts 
demonstrated a good safety and low toxicity, which highlighted the potential of this drug in 
CRPC treatment[57]. Furthermore, the interaction of AR with Hsp27 also facilitates AR 
translocation to the nucleus and its transactivation, thus contributing to PCa cell survival. 
Apartorsen (OGX-427), an antisense oligonucleotide inhibitor that targets Hsp27, disrupted 
the AR/Hsp27 interaction to promote the ubiquitin/proteasome-mediated degradation of AR 
and increase PCa cell apoptosis (Figure 1B)[58]. A phase I clinical trial of OGX-427 to treat 
CRPC demonstrated its good safety and tolerability[59]. Moreover, in a phase II clinical trial, 
OGX-427 was administered in combination with prednisone, a corticosteroid commonly used 
in PCa treatment. In this study, CRPC patients had decreased prostate-specific antigen (PSA) 
levels, though no changes in the proportion of CRPC patients without disease progression 
were observed after 12 weeks [59].  
Other PPIs involving AR have been disrupted. For instance, the cyclin-dependent kinase 5 
(Cdk5) has been considered a regulator of AR[60]. Indeed, Cdk5, by interacting with AR, 
enables its phosphorylation, resulting in the stabilization of AR. The reduction of AR/Cdk5 
interaction by roscovitine decreased PCa cells proliferation (Figure 1C)[61]. In addition, the 
combination of this compound with Akt inhibitors was associated with apoptosis of 
metastatic PCa cells[62]. Nevertheless, roscovitine were considered a pan-CDK inhibitor and 




4.1.2. B-cell lymphoma-2 (Bcl-2) protein family-related PPIs 
Upregulation of antiapoptotic B-cell lymphoma-2 (Bcl-2) family proteins is observed in almost 
all human tumors, including PCa, and seems to play key roles in apoptosis resistance, 
contributing to cancer progression[63–66]. These proteins exert their protective effects by 
the direct binding and sequestering of their pro-apoptotic counterparts (Bax, Bak and 
Bad)[67]. The overexpression of Bcl-2 was also observed in the progression of PCa to an 
androgen-independent stage (CRPC)[68]. Based on these roles in tumor progression, the 
inhibition of Bcl-2 protein family members represents a novel and promising therapeutic 
strategy for PCa and CRPC. The potential of Bcl-2 protein family members as therapeutic 
targets has long been considered, but many putative Bcl-2 inhibitors are non-specific, 
influencing other cellular targets. Besides, their non-mechanism-based toxicities also limit 
their effectiveness[67]. Nevertheless, some approaches to target Bcl-2 family-associated 
protein interactions have been developed (Table 1). 
The BH3 interacting motif, necessary for the interaction of Bcl-2 with its pro-apoptotic 
counterparts, is a major target for disruption. Several natural BH3 mimetics have been 
identified in the last years, including quercetin and gossypol. Quercetin proved successful in 
disrupting the Bcl-xL/Bax interaction, inducing the release of pro-apoptotic proteins, to 
trigger apoptosis in PCa cells (Figure 2A)[69]. A role in reversing the resistance to docetaxel, 
a drug used for CRPC treatment for over a decade, was also proposed[70]. Similarly, (-)-
gossypol inhibited PCa cell growth and induced apoptosis through mitochondrial pathways by 
blocking the Bcl-xL/Bax or Bad interactions (Figure 2A). Additionally, (-)-gossypol 
synergistically enhanced the antitumor activity of docetaxel and radiation therapy in vitro and 
in vivo,  suggesting its combination with other agents in PCa and CRPC treatment[71,72]. 
Subsequently, this compound was tested in phase I/II clinical trials though a limited efficacy 
was demonstrated. Despite the decrease in PSA levels observed in some patients, no 
objective response, according to RECIST guidelines, was observed[29]. Moreover, quercetin 
and (-)-gossypol were considered pan-assay interference compounds (PAINS), which have 
emerged as a limitation inherent of many natural products[73]. PAINS are compounds that 
appear in several high throughput screenings (HTS) against different targets, indicating that 
they have a wide range of cellular targets, which inhibit their development into successful 
probes, and makes them associated with several side effects[74]. There are a few examples 
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when it was possible to omit the “PAIN moieties” without loss of activity. However, this is an 
underexplored and limited approach and PAINS continue to be considered as false positives 
in many HTS[73,75].  
The fat-soluble vitamin α-tocopheryl succinate was also associated with BH3 mimetic activity. 
The treatment of PCa cells with this agent induced apoptosis associated with the disruption 
of the interaction of Bcl-xL and Bcl-2 with Bak (Figure 2A)[76]. This compound, despite its 
target multiplicity, seems to have a selective action in tumor cells. Indeed, minimal effects 
were observed in normal cells, however more detailed studies are still required[77]. The Bcl-
2 synthetic inhibitor ABT-737 was synthetized using structure-based design with BH3 region 
of Bad and has been considered a novel anticancer drug[78,79]. Like some natural Bcl-2 
inhibitors, ABT-737 inhibited the Bcl-2/Bax and Bcl-xL/Bak interactions, inducing apoptosis 
(Figure 2A)[79]. ABT-737 presented higher affinity than others Bcl-2 inhibitors and its major 
problem was associated with intrinsic resistance of PCa cells, caused by the expression of anti-
apoptotic Mcl-1 and additional apoptosis regulation pathways. This limitation was overcome 
by combining ABT-737 with other compounds that decrease Mcl-1 expression. In fact, ABT-
737, when combined with docetaxel and an immunotoxin, both inhibiting the expression of 
Mcl-1, improve the anticancer effects of these compounds[79,80]. This agent has also been 
tested for the treatment of other types of cancer and, in lung cancer, problems in drug 
delivery arise. To solve this problem, an oral version of ABT-737, named ABT-263, which share 
binding profile and affinities was developed and successfully tested[81].   
The disruption of Bcl-2/Bax was also successful with non BH3 mimetics, including diallyl 
trisulfide (DATS). Decreased interaction of Bcl-2/Bax, together with Bcl-2 phosphorylation and 
cleavage of procaspase-9 and-3, were associated with increased apoptosis of PCa cells 
incubated with DATS (Figure 2A)[82]. In vivo, the oral administration of this compound 
resulted in inhibition of tumor progression and pulmonary metastasis[83]. DATS also 
supressed AR function, which contributed to its effect on PCa progression[84]. This agent was 
considered promiscuous due to the modulation of multiple signaling pathways. Nevertheless, 
DATS seems to have higher cytotoxicity in PCa cells, compared with normal prostate cells[85]. 
Other strategies involving the disruption of Bcl-2 protein family members have also yielded 
positive outcomes for PCa treatment[86,87]. Bcl-2/Beclin-1 (Becn1) interaction represents a 
convergence point between apoptosis and autophagy. The interaction with Bcl-2 leads to the 
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repression of Becn1 pro-autophagic activity[88]. Besides its potential to disrupt PPIs between 
Bcl-2 family members[71], (-)-gossypol can also interrupt the interaction between Bcl-2 or Bcl-
xL and Becn1, releasing Bcn1, which triggered PCa cells autophagy (Figure 2B)[86]. This effect 
was confirmed in vivo, when the oral administration of (-)-gossypol significantly inhibited PCa 
growth in mice xenografts[86]. Moreover, 3-azido withaferin A (3-AWA), a derivative of the 
natural product withaferin, has been considered a strong anticancer candidate. This 
compound was considered a highly selective MMP-2 inhibitor and it seems to be through this 
effect that 3-AWA affects Bcl-2-associated PPIs. Several other targets have also been 
described for this compound[89,90] Indeed, Bcl-2/Becn-1 interactions were inhibited  in PCa 
cells incubated with 3-AWA, which sensitized PCa cells to apoptosis (Figure 2B)[87]. 
The targeting of other interactions involving pro-apoptotic Bcl-2 family proteins has been 
tested using different approaches[91–93]. The Ku70 protein, commonly associated with 
cancer progression and chemoresistance, has been recognized as a Bax suppressor[94]. 
Therefore, the natural flavonoid apigenin disrupted the Bax/Ku70 interaction, leading to 
increased Bax levels and consequently inducing PCa cells apoptosis, in vitro and in vivo (Figure 
2C)[91]. The apoptotic effect of apigenin in PCa cells was also mediated by disruption of Bad/ 
14-3-3β interaction (Figure 2D)[92]. A role in CRPC treatment was suggested for this 
compound[95]. Nevertheless, apigenin, like quercetin and gossypol was considered a PAINS, 
the wide range of intracellular protein targets limiting its success in drug development[96,97]. 
Furthermore, the inactivation of the Akt signaling axis achieved with DATS, resulted in the 
disruption of Bad/14-3-3β interaction ultimately leading to the apoptosis of PCa cells, and 
consequent beneficial effect (Figure 2D)[93]. 
4.1.3. Other transcription/ translation factors-related PPIs 
Targeting transcription factors to modulate aberrant gene expression in cancer has become 
a reality[96]. In PCa, several transcription and translation factors were associated with drug 
resistance, disease progression and metastasis[97]. Besides AR, mentioned in the previous 
section, PPIs involving other transcription/ translation factors have been blocked using 
different approaches. 
Adaptation to hypoxic microenvironments is a common feature of solid tumors. In PCa, 
hypoxia can drive disease progression and was associated with increased risk of invasion, 
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metastasis, treatment failure, and mortality[98,99]. Hypoxia-inducible factor 1 (HIF-1) is a key 
factor activated in hypoxic conditions to regulate the adaptative response of cancer cells to 
low oxygen concentrations[100]. Estrogen-related receptor alpha (ERRα), which is 
overexpressed in PCa, directly interacts with HIF-1α and inhibits its ubiquitination. As a result, 
the repression of ERRα/HIF-1α interaction by XCT790, a selective and potent ERRα inverse 
agonist, was associated with attenuation of ERRα-enhanced hypoxic PCa cells growth[101]. 
Moreover, different epidithiodiketopiperazines (ETPs), including gliotoxin, chaetoxin and 
chetomin, can also disrupt HIF-1α signaling. Indeed, ETPs blocked the interaction of HIF-1α 
with its coactivator p300, with consequent decrease of PCa tumor growth and angiogenesis 
in vitro and in vivo[102]. Due to its structure, it was suggested that ETPs may have other 
targets, which should be carefully analyzed in future studies[103]. 
The ability of ZNF433, which is overexpressed in most prostate tumors, to enhance β-catenin 
binding to transcription factor 4 (TCF4) is associated with PCa growth and migration, by 
regulating the expression of target genes[104]. This interaction was antagonized by a 
diterpenoid derivative - NC043, which directly targets CARF to block β-catenin/ TCF4,  
decreasing the malignant behaviour of PCa cells[105,106]. An impaired prostate 
tumorigenesis was also observed when mice xenografts were treated with NC043[106]. As 
previously mentioned, the Wnt/β -catenin pathway is one of the most significant pathways in 
CRPC initiation and progression and, thus, the potential of NC043 in CRPC treatment can be 
suggested[7]. Despite these promising results for NC043, as previously mentioned, targeting 
the Wnt pathway has been associated with several problems[55]. Furthermore, c-Myc, which 
is considered a key transcriptional effector of Wnt signaling, also contributes to prostate 
tumor progression, by promoting PCa cells survival. Thus, targeting c-Myc has been proposed 
as a potential therapeutic strategy for PCa[107]. , Despite the successfully inhibition of c-Myc/ 
Max by [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one (10058-F4) in vitro, no 
significant inhibition of tumor growth was observed in vivo after intravenous treatment with 
this compound [108,109]. The 10058-F4 compound was associated with a complete specificity 
for c-Myc/Max interaction and the lack of antitumor activity in vivo may have been caused by 
low concentration in tumor cells and/or by a rapid metabolism[109,110]. Thus, the 
formulation of this compounds needs optimization. Besides, it has been suggested that c-Myc 
drives the progression of CRPC, mainly by increasing the expression and activity of AR and AR 
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splice variants. Indeed, the inhibition of c-Myc sensitized enzalutamide-resistant PCa cells to 
growth inhibition[111]. Thus, 10058-F4 seems to have a potential role in CRPC treatment. 
Defects of the central translation process have also begun to be considered an important 
contributor to PCa development. Thus, targeting translation has become a novel approach for 
PCa treatment[112]. The repression of PPIs involving translation initiation factors has been 
associated with decreased tumor resistance to chemotherapy and castration[113,114]. The 
phenazine#14 compound, a natural compound that selectively disrupted the interaction 
between eukaryotic translation initiation factor 4E (eIF4E) and Hsp27, decreased the viability 
of chemo- and castration-resistant PCa cells[113]. This effect was confirmed in vitro and in 
vivo[113]. Similarly, in vitro incubation of PCa cells with dactolisib (BEZ235), a PI3K/mTOR 
inhibitor, disrupted eIF4E/eIF4G interaction, affecting cells chemoresistance[114]. The effect 
of this compound in PI3K/mTOR signaling suggests a potential role in CRPC treatment. 
4.1.4. Kinases/ phosphatases-related PPIs 
Because of their important roles in the vast majority of signal transduction processes, the 
potential of protein kinases and phosphatases as therapeutic targets has rightly been 
considered[115]. Protein kinases and phosphatases are often dysregulated in pathological 
conditions, including cancer[116]. Several protein kinases have been implicated in PCa cell 
survival and proliferation. Indeed, decreased PCa cell growth was observed after the specific 
knockdown of several protein kinases[117]. Some protein phosphatases have also been 
associated with PCa cell growth, differentiation, survival, and metastatic potential[118,119]. 
In particular, the blockage of various PPIs involving protein kinases and/or phosphatases has 
been associated with improved PCa outcomes[120–123]. 
The interaction between protein tyrosine kinase 2 beta (PYK2) and receptor tyrosine-protein 
kinase erbB-2 (ErbB-2) was associated with the adhesive ability of PCa cells and ERK/MAPK 
activity is a mediator of this effect[120]. Both the expression of a PYK2 mutant protein 
(K457A—PYK2) and the treatment of cells with a synthetic, potent and selective MEK inhibitor 
- PD98059 decreased PCa cell adhesion capacity by abolishing the PYK2/ErbB-2 interaction 
(Figure 3A)[120]. This compound also enhanced the docetaxel-induced apoptosis of CRPC 
cells, suggesting a beneficial role in the treatment of CRPC [124]. Moreover, the natural 
carbazole alkaloid mahanine, decreased PCa cell survival and proliferation by inhibiting the 
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interaction between Akt and DNA methyltransferases 1 (DNMT1) and 3B (DNMT3B)[121]. The 
repression of Akt/DNMTs interactions induced proteasomal degradation of DNMTs, with 
consequent demethylation of Ras-association domain family 1A (RASSF1A), restoring its 
expression and tumor suppressor activity (Figure 3B)[121]. Mahanine also disrupted AR 
signaling by inhibiting androgen-dependent and-independent transactivation, suggesting a 
potential role in CRPC treatment [125]. Despite these beneficial effects, mahanine was 
associated with a polypharmacological action, modulating multiple kinases, a feature that 
may limit mahanine-based drug development[126].  
PCa has been associated with a dramatic decrease in intracellular zinc levels, compared with 
benign prostate tissue[127]. Through cooperation with tumor suppressor p53, zinc repressed 
the interaction between HK2 and VDAC1, by activating GSK3β, resulting in PCa cell 
apoptosis[122]. This effect was confirmed in vivo, using a mice xenograft model (Figure 
3C)[122]. 
The protein phosphatase 2 (PP2A) has been implicated in the impairment of PCa cell growth. 
Indeed, decreased levels of PP2A were associated with increased PCa cell survival, growth and 
migration[128]. This protein associates with midline-1 (MID1) and the regulatory α4, forming 
a complex that mediates PP2A degradation[123]. By disrupting the PP2A/MID1/α4 complex, 
metformin increased PP2A activity to inhibit PCa cell growth and migration and reduce AR 
protein levels, suggesting beneficial effects to be used in PCa treatment (Figure 3D)[123]. 
Metformin has been described for the treatment of different pathologic conditions and is the 
most commonly prescribed treatment for Type 2 Diabetes[129]. More recently, a role in the 
treatment of different types of cancer has been proposed. This compound can interact with 
several metabolites and hormones and targets multiple signaling pathways with key roles in 
cancer initiation and progression[130]. Despite its target multiplicity, metformin was 
associated with a favourable toxicity profile with moderate side effects. A phase II clinical trial 
demonstrated a role of metformin in CRPC treatment, by inducing disease stabilization[131]. 
4.1.5. Other PPIs 
The disruption of additional PPIs are suggestive of alternative approaches for PCa 
treatment[132,133]. For instance, the targeting of Poly [ADP-ribose] polymerase 2 (PARP2), 
which is overexpressed in PCa, has been recognized as an efficient approach to inhibit AR 
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signaling, since PARP2 is a critical component of AR transcriptional machinery[134,135]. 
Indeed, blocking PARP2/FOXA1 interaction with 5-(2-oxo-2-phenylethoxy)-1(2H)-
isoquinolinone (UPF 1069), a synthetic selective inhibitor of PARP2, attenuated AR-mediated 
gene expression and inhibited AR-mediated PCa cell growth[132]. Because of the AR-
associated mechanism of action, a role of UPF 1069 in CRPC treatment was described[132]. 
In addition, the tankyrase protein (TNKS), also a member of the PARP family, was considered 
a crucial mediator of Wnt signal transduction associated with prostate tumorigenesis and 
disease aggressiveness[136]. TNKS is stabilized by interacting with ubiquitin-specific protease 
25 (USP25). The selective repression of this complex was achieved using a small molecule 
named C44, causing the reduction of PCa cell proliferation both in vitro and in vivo[133]. 
Through affecting Wnt signaling, which is crucial for the development of CRPC[7], a role of 
C44 in CRPC treatment can be hypothesized, however, it is important to consider the previous 
mentioned limitations associated with targeting Wnt pathway[55]. 
Increased PCa cells apoptosis was also observed when some PPIs were inhibited[137,138]. 
The synthetic small molecule inhibitor of apoptosis proteins (IAP) antagonist SH-130 was able 
to disrupt the interaction between X-linked IAP and Smac[137]. The incubation of PCa cells 
with SH-130, enhanced the radiation-induced apoptosis. This effect was confirmed in vivo 
using mice xenografts intravenously injected with SH-130. The injected mice overcame 
apoptosis resistance and the sensibilization to radiotherapy was improved[137]. CRPC was 
also associated with radiation resistance and IAPs seems to play a key role. Thus, SH-130 was 
also proposed for the treatment of CRPC. Indeed, IAP antagonists has been associated with a 
key role in overcome radiation and chemo-therapy resistance. For instance, these compounds 
increased sensitivity and amplified the apoptotic response to enzalutamide[139].  
DNA damage is a mechanism that can promote intrinsic cell apoptosis[140]. PARP inhibitors 
have been long proposed as anticancer therapies, due to the role of PARP in DNA damage 
repair. Inhibiting PARP leads to increase DNA damage, resulting in cancer cells apoptosis. 
Indeed, recently, two PARP inhibitors were approved by FDA for the treatment of PCa and 
CRPC[141]. The PARP inhibitor veliparib also demonstrated beneficial effects for the 
treatment of PCa. The E3 ubiquitin-protein ligase UHRF1/ Breast cancer type 1 susceptibility 
protein (BRCA1) complex, responsible for DNA damage repair, was disrupted by this 
compound, resulting in PCa cells apoptosis[138]. Recently, the dual PARP/HDAC inhibitor 
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treatment was suggested for anticancer treatment[142]. In fact, the co-administration of 
veliparib with the HDAC inhibitor SAHA in mice xenografts synergistically inhibited the 
prostate tumor growth[138]. 
Finally, the invasive and metastatic ability of PCa cells were also affected by disrupting 
different PPIs[143,144]. Simvastatin, one of the most common and extensively researched 
statins, prevented the interaction of PCa cells with the endothelium. Specifically, simvastatin 
represses the interaction between integrin αvβ3 and endothelial Intercellular Adhesion 
Molecule 1 (ICAM1), thus inhibiting PCa cell metastasis[143]. A role in delaying CRPC 
metastasis was also described for simvastatin[145]. Simvastatin is a drug commonly used to 
lower cholesterol and its main target is an enzyme involved in cholesterol synthesis[146]. This 
could lead to side effects, however high levels of circulating cholesterol was associated with 
an increased risk of aggressive PCa, which suggest that the simvastatin-mediated decrease in 
cholesterol levels is beneficial for PCa patients[147]. This compound is currently being studied 
in a phase I/II clinical trial for its potential use in PCa treatment (ClinicalTrials.gov Identifier: 
NCT00572468). Coordination of dynamic microtubules and actin filaments has been 
implicated in PCa cells invasion[148]. Therefore, the blockage of the drebrin/EB3 complex by 
3,5-bis(trifluoromethyl)pyrazole 2 (BTP2), a small molecule inhibitor of drebrin that bind to 
actin filaments, resulted in the decreased invasive ability of PCa cells[144]. Indeed, several 
pyrazole derivatives have been associated with anticancer activities and some of them were 
proposed as potential anticancer drugs[149]. 
4.2. PPIs targeted by peptides 
Larger macromolecules, including peptides, have long been proposed to disrupt PPIs. 
Traditionally, therapeutic peptides were derived from natural sources but, in more recent 
years, the solid phase synthesis of rationally-designed peptides has revolutionized molecular 
pharmacology[150]. The emergence of these macromolecules as new PPIs chemical inhibitors 
has also expanded the repertoire of druggable PPIs. The applications of peptides and peptide-
like materials to target PPIs aims to overcome the limitations associated with small molecules. 
The major advantages of peptides are their reduced immunogenicity, improved safety and 
high selectivity and potency[151]. Nonetheless, the application of peptides in living cells is 
often hampered by insufficient cell permeability and proteolytic instability[152]. More 
recently, these limitations have been overcome and the potential of peptides is growing 
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rapidly and, to date, there are over 60 peptide drugs approved[153]. The applications of 
peptides to disrupt several PPIs important for PCa progression are described in following 
sections (Table 2). 
4.2.1. Androgen receptor (AR)-related PPIs 
Recognition of the AR as the major therapeutic target in PCa has triggered the development 
of new and improved therapeutic strategies (Table 2)[154]. The repression of AR interaction 
with its co-activators has demonstrated effects in the impairment of PCa progression[155–
157]. A synthetic peptide mimicking the structure of SRC-1 was able to selectively disrupt the 
AR interaction with its co-activators SRC-1 and SRC-2, to decrease PCa cells proliferation 
(Figure4A). In addition to reducing AR and AR variant V-7 transactivation, this peptide also 
inhibited the AR-dependent expression of PSA in a CRPC cell line, suggesting its utilization in 
CRPC treatment[155]. The proline-glutamic acid- and leucine-rich protein 1 (PELP1) is also a 
co-activator of AR and its interaction involves the LXXLL motif. The AR/PELP1 interaction was 
disrupted by a peptidomimetic, named D2, containing the LXXLL binding motif[156]. D2 
blocked the androgen-induced nuclear uptake and genomic activity of AR, with a consequent 
abrogation of PCa cells proliferation (Figure 4A). This beneficial effect was confirmed in vivo, 
using a mouse xenograft model. In addition to these beneficial effects, this compound was 
considered stable, non-toxic and efficiently taken up by PCa cells, highlighting its potential 
use in PCa treatment[156]. The PPI between the AR and its coactivator gelsolin (GSN) was also 
disrupted by mimetic peptides containing either the whole or partial DNA or ligand binding 
domain. Such peptides blocked the AR/GSN interaction resulting in suppression of GSN-
enhanced AR activity (Figure 4A)[157]. However, the authors highlighted the possible 
disruption of other interactions of AR with its regulators using these peptides, since the region 
covered by the peptides is common to the interaction with several AR regulators. These 
effects needs to be carefully analyzed[157]. 
Other AR interacting proteins seem to play a role in PCa pathogenesis. By disrupting the 
interaction of AR with SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily E member 1 (BAF57), the BIPep, a NH2-terminal inhibitory peptide of 
BAF57, antagonized AR function and, consequently, decreased PCa cells proliferation (Figure 
4B)[158]. In addition, PCa cells proliferation was also strongly impaired by a peptide that 
targeted the SH3 binding motif. This motif mediates the interaction of AR with the proto-
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oncogene tyrosine-protein kinase Src (Figure 4C). The intraperitoneal injection of the same 
peptide into a mouse xenograft suppressed the tumor growth, corroborating a beneficial 
effect in PCa treatment[159]. Finally, the serine/threonine-protein kinase 4 (MST1) is 
considered a negative regulator of the interaction between AR and Yes-associated protein 1 
(YAP1). YAP1 is considered a key effector of Hippo pathway and, by interacting with AR 
conferred castration-resistance to PCa[8]. Thus, MST1 seems to play a role in CRPC treatment. 
Indeed, the repression of AR/YAP1 interaction by MST1 decreased the proliferation of 
invasive CRPC cells (Figure 4D)[160].  
4.2.2. Kinases/ phosphatases-related PPIs 
The blockage of PPIs involving protein kinases or phosphatases, with the ultimate goal of 
impairing PCa progression, has also been achieved using peptides[161–164]. As kinases and 
phosphatases often have docking sites outside their active site, selective peptides can be 
engineered to mimic these unique PPI interfaces. Thus, it is possible for peptides to disrupt 
kinase/phosphatase-related PPIs without compromising the efficient catalysis of the active 
site[150]. The nonapeptide KRX-123 disrupted the interaction between Lyn kinase and its 
substrates by targeting a unique interaction site within Lyn, resulting in decreased PCa cells 
proliferation (Figure 5A)[161]. The PCa tumor regression was observed after intravenous 
injection of KRX-123 in a PCa mice xenograft model, corroborating the in vitro results. Lyn was 
considered a prime target for CRPC, which led authors to suggest KRX-123 for CRPC treatment 
[161]. Moreover, the destabilization of Nm23-H1/h-Prune interaction by a competitive 
permeable peptide (CPP) resulted in increased PCa cells apoptosis in vitro and inhibited 
metastasis in vivo (Figure 5B). The CPP was also associated with inhibition of Akt/mTOR and 
NF-kB signaling pathways, which suggests that this peptide could have multiple targets[162]. 
Lastly, when phosphorylated by Akt, a forkhead box protein O1 (FOXO1)-derived peptide 
inhibitor bound to Ras GTPase-activating-like protein IQGAP1 (IQGAP1), suppressing the 
IQGAP1/MAPK interaction. The blockage of this PPI proved to be successful in suppressing 
the taxane chemoresistance (Figure 5C)[163]. 
The blockage of the signaling of protein phosphatases with peptides has also shown beneficial 
effects. The interaction of phosphatidylinositol 3,4,5-triphosphate 5-phosphatase 2 (Ship 2) 
with the Ephrin type-A receptor 2 (EphA2) receptor tyrosine kinase, based on their Sam 
domains, can be disrupted by the (KRI)3 peptide conjugated with a cell penetrating sequence 
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and a fluorescent probe – FITC-TAT-(KRI)3 peptide. By damaging the PCa cells plasma 
membrane, the FITC-TAT-(KRI)3 peptide increased the PCa cells necrosis in vitro, contributing 
to the reduction of tumor growth (Figure 5D)[164]. 
4.2.3. Other PPIs 
The disruption of other PPIs, involving different types of proteins with critical roles in PCa 
progression, has proven successful in the suppression of disease progression. Targeting Rho 
GTPase guanine nucleotide exchange factor Vav3 (Vav3), which is overexpressed in PCa, has 
been recognized as an efficient approach to inhibit AR signaling[165]. Indeed, blocking 
Vav3/cell division cycle 37 homolog (Cdc37) interaction, by using a peptide corresponding to 
Vav-3 binding region of Cdc37, attenuated AR transcriptional activity and inhibited PCa cells 
proliferation. A role of this interaction in the progression of PCa to CRPC was proposed by 
authors, who suggested the potential use of the synthesized peptide in CRPC treatment[166]. 
More recently, peptide macrocycles (peptoids) have emerged to improve the disruption of 
PPIs, by mimicking protein secondary structure motifs. A peptoid that binds to a pocket in the 
interface between TCF and β-catenin was able to suppress this interaction, inhibiting Wnt and 
AR signaling, with consequent suppression of cells proliferation[167]. The inhibition of Wnt 
signaling was confirmed in vivo using a zebrafish model[167]. The effect of the synthesized 
peptoid in Wnt signaling suggested a potential role in CRPC treatment. Nevertheless, as 
mentioned in previous section, problems with targeting Wnt signaling could emerge[55]. 
The interaction of CC chemokine receptor-9 (CCR9) with its natural ligand CCL25 was 
associated with the upregulation of anti-apoptotic proteins and inhibition of cytotoxic effects 
of etoposide, an anticancer chemotherapeutic drug, which demonstrated beneficial effects in 
the CRPC treatment[168]. Blocking this interaction, using a CCL25 neutralization peptide 
antibody, impaired the antiapoptotic mechanisms, inducing PCa cells apoptosis. The 
combined treatment of CRPC mice xenografts with etoposide and CCL25 antibody significantly 
decreased the tumor burden, suggesting a beneficial effect of this peptide as an adjuvant 
therapy for CRPC[168]. The invasive ability of PCa cells was also impaired by disrupting PPIs 
using peptides. Indeed, the repression of Wiskott-Aldrich syndrome protein family member 3 
(WASF3)/ Cytoplasmic FMR1-interacting protein 1 (CYFIP1) complex, using stapled peptides 
that target an α-helical interface, decreased PCa cells invasion in vitro, indicating a beneficial 
role in inhibiting PCa metastasis[169]. 
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5. Other PPIs with potential to be disrupted in PCa 
Beyond the PPIs whose disruption has already been tested, others have been identified as 
promising therapeutic targets for PCa (Table 3). Besides interactions of AR with its 
coactivators, PPIs between AR and other proteins have been correlated with important roles 
in PCa progression[170–177]. As examples, the interactions of AR with signal transducer and 
activator of transcription 3 (STAT3) and peroxiredoxin-1 (PRDX1) were associated with 
increased AR transcriptional activity and PCa progression[170,171]. In addition, AR/ 
transcription factor SOX-9 (SOX9), AR/ N-acetyltransferase arrest-defect 1 protein (ARD1), 
and AR/ semenogelin I (SEMG1) interactions were associated with increased PCa cells 
proliferation[172–174]. Some protein phosphatases/ kinases have been considered AR 
coactivators[175,176]. In particular, serine/threonine-protein phosphatase PP1 (PP1), by 
interacting with AR, suppressed its ubiquitin-mediated proteasome degradation. The AR 
interaction with zipper interacting protein kinase (ZIPK) also increased AR-mediated 
transcriptional activity and ZIPK contributed to anti-apoptotic and proliferative functions of 
AR in PCa cells[177]. 
Additional interactions involving protein phosphatases/ kinases have also been considered as 
promising therapeutic targets for PCa, although their disruption has not yet been tested[178–
182]. PP1 interacts with several proteins with important outcomes for PCa progression. The 
PP1/caveolin-1 (CAV1) interaction is associated with PP1 inhibition and was responsible for 
CAV1-mediated PCa cells survival[178]. In addition, the tyrosine-protein kinase Fer (FER) 
interaction with PP1 contributed to cell cycle progression of malignant PCa cells[179]. Finally, 
PP1 interacts with nuclear inhibitor of protein phosphatase 1 (NIPP1) and this interaction 
plays a key role to increase and direct the migration of PCa cells, thus contributing to 
metastasis[180]. A role in chemotherapeutic drug resistance was also evident for some PPIs 
involving protein kinases. In fact, both MST1/ HSP70 and protein kinase C (PKC)/ 
Ectonucleoside triphosphate diphosphohydrolase 5 (PCPH) interactions promoted resistance 
to cisplatin-induced PCa cells apoptosis[181,182]. The PKC/PCPH interaction was also 
associated with increased PCa invasiveness[182]. 
Other PPIs have also been considered potential therapeutic targets for PCa. The bradykinin 
receptor 1 (B1R)/ B2R, S100A9/ Toll-like receptor 4 (TLR4), Tripartite motif-containing protein 
25 (TRIM25)/ GTPase-activating protein-binding protein 2 (G3BP2) and Runt-related 
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transcription factor 2 (RUNX2)/ SMAD interactions promoted PCa tumor growth[183–186]. 
Besides this effect, the interaction of RUNX2 with SMAD also controlled the PCa metastatic 
process[186]. Other PPIs, namely Annexin A2 (ANXA2)/ STAT6 and Cluster of differentiation 
44 (CD44)/ Vascular cell adhesion molecule 1 (VCAM1) played an important role in PCa 
metastasis[187,188]. In particular, the interaction of CD44 with VCAM1 mediated the 
adhesion of PCa cells to vascular endothelial cells, a key initial step in metastatic process[188]. 
Lastly, the interaction between Prostate Leucine Zipper gene (PC1) and initiation factor 4E-
binding protein 1 (4EBP1) conferred resistance to rapamycin treatment[189]. 
6. Concluding remarks and future perspectives 
The disruption of PPIs has emerged as a promising approach for anticancer therapies. 
Nevertheless, the lack of cancer-specific analysis in PPIs databases has limited this approach. 
Besides, the process of developing a PPI inhibitor remains long and difficult. Interrupting AR-
related PPIs seems to be a promising strategy since AR assumes a key role in PCa progression. 
Several small molecules were suggested for this purpose and beneficial results were observed 
either alone or in combination with other chemotherapeutic drugs. On the other hand, 
despite the potential of targeting Bcl-2-related PPIs to promote PCa cells apoptosis and 
despite the largest number of compounds developed to target them, most of the compounds 
lack selectivity and some were even considered PAINS. These findings have limited the 
development of compounds that effectively targets Bcl-2-associated PPIs, since most were 
associated with toxicity and off-target effects. Other small molecules that target 
kinases/phosphatases-related PPIs or other PPIs were also associated with promising results, 
although some are limited by target multiplicity or by affecting the Wnt pathway. 
Peptides emerged more recently as a favourable strategy to target PPIs. Developed to 
circumvent the main limitations of small molecules, peptides have been associated with 
relatively few off-target effects. Most of the peptides developed to target PPIs were 
synthesized to mimic the structure of the PPI interface and often exhibit exquisite specificity 
and affinity to their targets. Nevertheless, most of them lack detailed target engagement data 
and more information is still required to confirm their potential. 
Among the 28 small molecules and 14 peptides proposed for the treatment of PCa, some 
were associated with a role in CRPC treatment. In addition, we highlighted the potential role 
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of several compounds in the treatment of CRPC which interfere with signaling pathways 
dysregulated in this more aggressive cancer type. The discovery of new therapeutic options 
for CRPC remains a significant challenge of PCa treatment, but most of the compounds 
described to date were tested in cell lines, including PC-3 and LNCaP, that are not considered 
CRPC models. Similarly, some authors claim that the DU-145 cell line, used to evaluate some 
of the compounds described herein, is a useful model of CRPC.  However, since this cell line 
does not express AR, the main driver of CRPC initiation and progression, any conclusions 
drawn from such studies are limited. Thus, ailanthone, UPF1069, SRC1-derived peptide and 
MST1 kinase were the only compounds tested in CRPC cell lines (22RV1 or C4-2) with 
promising results. Moreover, OGX-427 and metformin were successfully tested in phase I/II 
clinical trial for CRPC treatment and the phase I clinical trial of simvastatin is currently 
ongoing. 
In conclusion, the targeting of PPIs as a PCa therapeutic option, either as a monotherapy or 
in combination with other therapeutic agents, remains a challenging, but promising approach 
and is a topic with many open doors. Maximizing the range of PPIs that can be targeted will 
be crucial to exploit the wide variety of intracellular molecular targets and potential drug 
targets of the future. Structure-based studies of PPI interfaces are also essential to improve 
the effectiveness of targeting strategies. Thus, more research and advancement are urgently 
required to develop improved assays to modulate PPIs and develop a new and effective 
therapeutic strategy for PCa and CRPC. 
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Table 1: Summary of the small molecules used to the disruption of protein-protein interactions critical for progression of prostate cancer. The respective output of the 












[91] - - - 




induce PCa cells 
apoptosis 






induces PCa cells 
apoptosis 

















































[108] - - - No data Potential role 



















↓ viability and ↑ death 





















abolish adhesive ability 
of PCa cells 











↓ PCa cells proliferation, 
survival 




p53 and zinc HK2/ VDAC 
DU145, 
PC-3 












↓ PCa cells proliferation 
and migration; ↓ AR 
protein levels 
























↓ PCa cells proliferation 
mice 
(xenografts) 
inhibit PCa cells 
proliferation 










to X-ray radiation 









↓ PCa cells colony 





































   In vitro Pre-clinical validation   
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peptidomimetics 
D2 
AR/ PELP1 LNCaP ↓ PCa cells proliferation 
mice 
(xenografts) 
Inhibits tumor growth [158] - 
AR peptides AR/GSN 
LNCaP, PC-3, 
DU145 
suppression of GSN-enhanced AR 
activity 
- - [159] - 
BiPep AR/ BAF57 
LNCaP, PC-3, 
DU145 
↓ PCa cells proliferation - - [160] - 
Peptide (10 
aminoacid) 
AR/ SRC LNCaP ↓ PCa cells proliferation 
mice 
(xenografts) 
inhibits tumor growth [161] - 






Lyn interactions DU145, PC-3 inhibit PCa cells proliferation 
mice 
(xenografts) 




PC-3 ↑ apoptosis of PCa cells 
mice 
(xenografts) 






suppression of chemoresistance - - [165] - 
Peptide (FITC-
TAT-(KRI)3) 




Cdc37/ Vav3 PC-3, LNCaP ↓ PCa cells proliferation - - [168] Potential role 
Peptoids TCF/ B-catenin LNCaP inhibit PCa cell growth zebrafish inhibit Wnt signaling [169] Potential role 
CCL25 neut. 
antibody 
CCR9/ CCL25 LNCaP, PC-3 induce apoptosis 
mice 
(xenografts) 
↑ drug efficacy in refractory 
PCa 
[170] Described role 
peptides 
(WAHM1 and 2) 
WASF3/ CYFIP1 PC-3, DU145 ↓ PCa cells invasion - - [171] - 
 
Table 2: Summary of the peptides used to the disruption of protein-protein interactions critical for progression of prostate cancer. The respective output of the protein 









AR/ STAT3 LNCaP (in vitro) enhance AR transcriptional activity [172] 
AR/ PRDX1 LNCaP and DU145 (in vitro) ↑ AR transactivation [173] 
AR/ SOX9 LNCaP and PC-3 (in vitro) ↑ AR protein expression; promotes PCa cells growth [174] 
AR/ ARD1 LNCaP (in vitro) and human PCa tissue (in vivo) 
↑ AR transactivation; contributes to PCa cells 
proliferation 
[175] 
AR/ SEMG1 LNCaP (in vitro) 







LNCaP (in vitro) 
↓ proteasome-mediated AR degradation; ↑ AR-
mediated gene transcription 
[177]  
LNCaP and PC-3 (in vitro) 
supress AR ubiquitylation and degradation; enhance AR 
activity 
[178] 
AR/ ZIPK LNCaP and PC-3 (in vitro) ↑ AR-mediated transcription [179] 
  
PP1/ CAV1 LNCaP (in vitro) promotes PCa cells survival [180] 
PP1/ FER PC-3 (in vitro) promotes PCa cells cycle progression [181] 
PP1/ NIPP1 PC-3 (in vitro) ↑ and direct PCa cells migration [182] 
MST1/ HSP70 LNCaP (in vitro) induce PCa cells cisplatin resistance [183] 
PKC/ PCPH LNCaP and PC-3 (in vitro) 
↑ invasiveness of PCa and resistance to cisplatin-
induced apoptosis of PCa cells 
[184] 
Other PPIs 
B1R/ B2R PC-3 (in vitro) induce PCa cells proliferation [185] 
S100A9/ TLR4 TRAMP mice model (in vivo) promotes PCa tumor growth [186] 
TRIM25/ G3BP2 LNCaP and 22Rv1 (in vitro) enhances PCa cell survival and growth [187] 
RUNX2/ SMAD PC-3 (in vitro) mediates tumor growth and metastasis [188] 
ANXA2/ STAT6 LNCaP, DU145 and PC-3 (in vitro) 
potential implications in PCa progression and metastatic 
process 
[189] 
CD44/ VCAM1 PC-3, DU-145 (in vitro) 
mediates the adhesion of PCa cells with vascular 
endothelial cells 
[190] 
PC1/ 4EBP1 LNCaP and C4-2 (in vitro) 
enhances PCa cells survival and progression and ↑ 
chemoresistance 
[191] 
Table 3: Summary of the protein-protein interactions implicated in the progression of PCa and whose disruption has not yet been tested. The role of the 

















Figure 1: Summary of androgen receptor-related protein-protein interactions, their disruption by 
small molecules and associated therapeutic outcomes in prostate cancer cells. A: The disruption of 
the interaction between AR and its co-activators β-catenin by iCRT3 inhibits AR-mediated gene 
expression, resulting in decreased PCa cells proliferation. The same effect was observed for the 
disruption of AR/ SRC1 and GRIP1 by PTER-ITC conjugate; B: The blockage of AR interaction with HSP27 
and 90 is achieved by OGX-427 and ailanthone, respectively, resulting in proteasome-degradation of 
AR, inhibiting its translocation to the nucleus and respective promotion of PCa cells proliferation; C: 
The disruption of AR/CDK5 interaction by roscovitine leads to reduction of PCa cells proliferation. 


























Figure 2: Summary of the Bcl2 protein family-related protein-protein interactions disruption by 
small molecules and the respective outcomes in prostate cancer cells. A: The disruption of the 
interaction between Bcl-2 (or Bcl-xL) with its pro-apoptotic counterparts (Bax, Bad or Bak) by quercetin 
leads to cytochrome c release from the mitochondria and consequent caspases activation, resulting 
in PCa cells apoptosis. Other compounds, namely (-)-gossypol, α-tocopheryl-succinate, ABT-737 and 
diallyl-trisulfide have the same outcome in PCa cells; B: The disruption of the Bcl-2/ Becn1 interaction 
by 3-AWA results in PCa cells death by autophagy. (-)-gossypol also produces the same effect; C: The 
interruption of Ku70/ Bax interaction by apigenin releases cytochrome c from the mitochondria, 
conducing to PCa cells apoptosis; D: The disruption of Bad/ 14-3-3β by diallyl-trisulfide also contributes 
to PCa cells apoptosis. The same effect is observed with PCa cells incubation with apigenin. 












Figure 3: Summary of the kinases/phosphatases-related protein-protein interactions disruption by 
small molecules and the respective outcome in prostate cancer cells. A: The disruption of the 
interaction between ErbB2 and PIK2 by PD98059 dephosphorylated PIK2 and consequent inhibit PCa 
cells adhesive ability; B: The blockage of the interaction between DNMT1 and DNMT3B 
dephosphorylated DNMTs, leading to its proteasome-mediated degradation and consequent 
inhibition of PCa cells proliferation; C: The zinc, in combination with p53 activates GSK3β, which 
phosphorylate VDAC1 and consequent inhibits its interaction with HK2 resulting in PCa cells apoptosis; 
D: The disruption of MID1-α4/PP2A interaction increases the activity of PP2A, inhibiting the 
proliferation of PCa cells. 









Figure 4:  Summary of androgen receptor-related protein-protein interactions, their disruption by 
peptides and associated therapeutic outcomes in prostate cancer cells.  A: The disruption of the 
interaction between AR and its co-activators SRC1 and 2, PELP1 and GSN by peptides based on the 
protein-protein interactions binding regions - SRC-1 derived peptide, D2 and AR peptides, respectively, 
inhibits AR transactivation and consequently decrease PCa cells proliferation. B,C:  The blockage of the 
interaction of AR with BAF57 (B) and SRC (C) by an inhibitory peptide of BAF57 and a peptide covering 
AR-binding motif of SRC, respectively, conduce to reduction of proliferation; D: The interruption of 
AR/YAP1 interaction by MSTK1 also inhibits PCa cells proliferation. 








Figure 5: Summary of kinases/phosphatases-related protein-protein interactions, their disruption 
by peptides and associated therapeutic outcomes in prostate cancer cells. A: The disruption of the 
interaction between LYN and its substrates (LYNS), which are  phosphorylated by LYN,  by KRX-123 
peptide resulted in inhibition of PCa cells proliferation; B: The interruption of Nm23-H1/ h-Prune 
interaction by a competitive permeable peptide (CPP) dephosphorylated Nm23-H1, leading to 
inhibition of metastasis and PCa cells apoptosis; C: The blockage of IQGAP1/MAPK interaction by the 
AKT-phosphorylated FOXO-1 derived peptide conduce to Inhibition of chemoresistance; D:  The 
disruption of SHIP2/ EPHA2 interaction by FITC-TAT-(KRI)3 resulted in PCa cells necrosis. 
Abbreviations: PCa: prostate cancer; 
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